Oral antiviral pills from Merck & Co and Pfizer Inc-BioNTech SE have been shown to significantly blunt the worst outcomes of COVID-19 if taken early enough, but doctors warn vaccine hesitant people not to confuse the benefit of the treatments with prevention afforded by vaccines.
While 72 percent of American adults have gotten a first shot of the vaccine, according to a Kaiser Family Foundation poll, the pace of vaccination has slowed, as political partisanship in the United States divides views on the value and safety of vaccines against the coronavirus.
Vaccine mandates by employers, states and the administration of US President Joe Biden have helped increase vaccinations but also fueled that controversy.
Some disease experts fear the arrival of oral COVID-19 treatments may further impede vaccination campaigns. Preliminary results of a survey of 3,000 US citizens by the City University of New York (CUNY) School of Public Health suggest the drugs could hamper the effort to get people vaccinated, said Scott Ratzan, an expert in health communication at CUNY, who led the research.
Ratzan said one out of every eight of those surveyed said they would rather get treated with a pill than be vaccinated. That is a high number.
The concern follows news on Friday from Pfizer, maker of a leading COVID-19 vaccine, that its experimental antiviral pill Paxlovid cut the risk of hospitalization and death from the disease by 89 percent in high-risk adults.
Pfizer’s results followed news from Merck and partner Ridgeback Biotherapeutics on October 1 that their oral antiviral drug cut hospitalization and death by half. That drug, known as molnupiravir, won conditional approval in the UK on Thursday. Both need clearance from US health regulators but could be on the market in December.
“By relying exclusively on an antiviral drug, it’s a bit of a roll of the dice in terms of how you will do. Clearly, it’s going to be better than nothing, but it’s a high-stakes game to play,” said Dr Peter Hotez, a vaccine expert and professor of molecular virology and microbiology at Baylor College of Medicine.
Six infectious disease experts interviewed by Reuters were equally enthusiastic about the prospect of effective new treatments for COVID-19 and agreed they were no substitute for vaccines.
Even in the face of the highly transmissible Delta variant of the virus, the vaccines from Pfizer-BioNTech remain effective, cutting the risk of hospitalization by a combined 86.8 percent, according to a government study of US veterans.
They said some unvaccinated people have already relied on monoclonal antibodies, drugs that need to be delivered through intravenous IV infusions or injections, as a backstop in case they become infected.
“I think the Pfizer news is terrific news. It goes hand in hand with vaccination. It doesn’t replace it,” said Dr Leana Wen, an emergency physician and public health professor at George Washington University and Baltimore’s former health commissioner.
Choosing not to get vaccinated would be a tragic mistake, said Albert Bourla, chief executive officer of Pfizer Inc.
ARR
